Steven Shak Sells 25,000 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $68.53, for a total value of $1,713,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Steven Shak also recently made the following trade(s):

  • On Monday, April 1st, Steven Shak sold 75,000 shares of Genomic Health stock. The shares were sold at an average price of $68.56, for a total value of $5,142,000.00.
  • On Monday, March 4th, Steven Shak sold 32,500 shares of Genomic Health stock. The stock was sold at an average price of $76.91, for a total value of $2,499,575.00.
  • On Thursday, February 28th, Steven Shak sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $76.50, for a total value of $3,825,000.00.
  • On Monday, February 4th, Steven Shak sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $76.29, for a total value of $3,814,500.00.
  • On Thursday, January 31st, Steven Shak sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $74.24, for a total value of $3,712,000.00.

GHDX stock traded down $0.81 during midday trading on Wednesday, reaching $65.12. 363,158 shares of the company traded hands, compared to its average volume of 461,462. Genomic Health, Inc. has a 52-week low of $31.16 and a 52-week high of $92.18. The company has a market cap of $2.43 billion, a PE ratio of 62.02 and a beta of 0.95.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.02. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. The firm had revenue of $104.56 million for the quarter, compared to the consensus estimate of $101.55 million. During the same period in the prior year, the business posted $0.05 earnings per share. The company’s revenue for the quarter was up 22.0% on a year-over-year basis. Equities research analysts expect that Genomic Health, Inc. will post 1.49 earnings per share for the current fiscal year.

GHDX has been the topic of a number of recent analyst reports. ValuEngine lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 5th. BidaskClub lowered Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. Zacks Investment Research lowered Genomic Health from a “buy” rating to a “hold” rating in a research report on Tuesday. Piper Jaffray Companies boosted their target price on Genomic Health to $86.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $97.00 target price (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. Ten equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Genomic Health presently has an average rating of “Hold” and an average target price of $63.13.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royce & Associates LP increased its holdings in Genomic Health by 22.8% during the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares during the period. Advisor Group Inc. boosted its position in Genomic Health by 34.9% during the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 516 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Genomic Health during the 3rd quarter valued at $171,000. Quantamental Technologies LLC bought a new stake in Genomic Health during the 4th quarter valued at $180,000. Finally, Trexquant Investment LP bought a new stake in Genomic Health during the 3rd quarter valued at $202,000. Institutional investors own 90.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Steven Shak Sells 25,000 Shares of Genomic Health, Inc. (GHDX) Stock” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/genomic-health-inc-ghdx-insider-steven-shak-sells-25000-shares-of-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Read More: What Does Beta Mean In Stock Selection

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.